Poor glycemic control

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34

Hyperlipidemia at baseline was associated with a 19% higher risk of persistently poor glycemic control (HbA1c >9%) over the study period (RR: 1.19, 95% CI: 1.06-1.34).

Effect: decline; RR: 1.19; CI: 95% CI: 1.06, 1.34